Literature DB >> 28738426

Long Term Effects of Liraglutide in Japanese Patients with type 2 Diabetes Among the Subgroups with Different Renal Functions: Results of 2-Year Prospective Study.

Takeyuki Hiramatsu1, Akiko Ozeki1, Hideaki Ishikawa1, Shinji Furuta1.   

Abstract

Aims Very few studies have ever examined the effects of long-term (>1 year) administration of liraglutide in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Therefore, we conducted a 2-year study to prospectively examine the effects of liraglutide in those patients. Methods A total of 148 patients with T2DM were enrolled and treated with liraglutide (0.6 or 0.9 mg/day). 97 patients completed the 2-year study without protocol deviations. These patients were divided into 3 groups according to the baseline estimated glomerular filtration ratio (eGFR) (in mL/min/1.73 m2): group A, ≥60 (n=39); group B, ≥30 to <60 (n=38); and group C, <30 (n=20). The changes in blood and urine variables, and echocardiographic left ventricular mass index (LVMI) from baseline to 2 years were analyzed in each group. Primary outcomes were changes of the renal parameters of eGFR and albuminuria after the treatment of liraglutide. Results Blood glucose and systolic blood pressure decreased significantly after 24 months of liraglutide treatment in all groups compared with baseline (p<0.05). The eGFR increased significantly in group B (p<0.05), and remained unchanged in groups A and C. Albuminuria and LVMI decreased significantly in all 3 groups compared with baseline (p<0.05). Conclusions These findings suggest that 2 years of liraglutide treatment in Japanese patients with T2DM and impaired renal function was effective in terms of suppressing the deterioration of renal function, and reducing albuminuria. Long-term liraglutide treatment also improved glycemic control and blood pressure, and reduced left ventricular hypertrophy in this study. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28738426     DOI: 10.1055/s-0043-110603

Source DB:  PubMed          Journal:  Drug Res (Stuttg)        ISSN: 2194-9379


  4 in total

1.  Increasing Mortality in Adults With Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria.

Authors:  Holly Kramer; Robert E Boucher; David Leehey; Linda Fried; Guo Wei; Tom Greene; Sylvia E Rosas; Richard Cooper; Guichan Cao; Srinivasan Beddhu
Journal:  Diabetes Care       Date:  2018-02-07       Impact factor: 19.112

2.  Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.

Authors:  Takeyuki Hiramatsu; Yuko Asano; Masatsuna Mabuchi; Kentaro Imai; Daiki Iguchi; Shinji Furuta
Journal:  Eur J Clin Invest       Date:  2018-08-16       Impact factor: 4.686

3.  Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.

Authors:  Takeyuki Hiramatsu; Hiroki Ito; Shota Okumura; Yuko Asano; Daiki Iguchi; Shinji Furuta
Journal:  Diab Vasc Dis Res       Date:  2020 Nov-Dec       Impact factor: 3.291

4.  Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.

Authors:  Xiao-Min Chen; Wen-Qiang Zhang; Yuan Tian; Li-Fen Wang; Chan-Chan Chen; Chuan-Mei Qiu
Journal:  Cardiovasc Diabetol       Date:  2018-04-10       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.